Repatha

ApprovedSmall molecule

UUniversity of California, Los Angeles

Repatha is one of 32 small molecule programs targeting Atherosclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtherosclerosisActive, not recruiting

AtherosclerosisApproved

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Atherosclerosis

#DrugCompanyPhaseTrials

Avandia

Alnylam Pharmaceuticals

Phase 3

3 2

Estrace

Novo Nordisk

Phase 3

2 3

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 4

Glucotrol

Pfizer

Phase 3

1 5

Actemra

Roche

Phase 3

1 6

Brilinta

AstraZeneca

Phase 3

1 7

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

2 8

Zontivity

Akero Therapeutics

Phase 3

2 9

Colestid

Pfizer

Phase 3

2 10

Aspirin 75

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atherosclerosis1 trial

Reducing Intracranial atheroSclErosis With Repatha

Terminated·UUniversity of California, Los Angeles·Phase 4·NCT04573777·10 enrolled

STEMI1 trial

Evolocumab in STEMI

Active, not recruiting·SSejong General Hospital·Phase 3·NCT06081803·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Repatha. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Repatha compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Repatha. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, Los Angeles

Repatha

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atherosclerosis1 trial

STEMI1 trial

References

Drug Info

Quick Facts

Related News